Corrigendum to ‘Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival’: [Annals of Oncology Volume 32, Issue 8, August 2021, Pages 1015-1024](S0923753421015532)(10.1016/j.annonc.2021.05.353)

D. J. Slamon, P. Neven, S. Chia, G. Jerusalem, M. De Laurentiis, S. Im, K. Petrakova, G. Valeria Bianchi, M. Martín, A. Nusch, G. S. Sonke, L. De la Cruz-Merino, J. T. Beck, Y. Ji, C. Wang, U. Deore, A. Chakravartty, J. P. Zarate, T. Taran, P. A. Fasching

Research output: Contribution to journalComment/debate

2 Scopus citations

Abstract

The authors regret that at the time the article was published, Supplementary Table S2 contained errors. This has now been corrected. The authors would like to apologise for any inconvenience caused.

Original languageEnglish
Pages (from-to)1307
Number of pages1
JournalAnnals of Oncology
Volume32
Issue number10
DOIs
StatePublished - Oct 2021

Bibliographical note

Publisher Copyright:
© 2021 The Author(s)

Fingerprint

Dive into the research topics of 'Corrigendum to ‘Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival’: [Annals of Oncology Volume 32, Issue 8, August 2021, Pages 1015-1024](S0923753421015532)(10.1016/j.annonc.2021.05.353)'. Together they form a unique fingerprint.

Cite this